[ad_1]
Harmony – Agencies
NEW YORK (Reuters Health) – An experimental drug used to prevent several types of cancer has proven effective in preventing stomach cancer, according to a recent US study.
The study was conducted by researchers at the Vanderbilt University Medical Center in the United States of America, and published their findings in the latest issue of Proceedings of the National Academy of Sciences. The team studied the effectiveness of the drug, called DFMO, and used a preventive treatment to fight against cancer.
Experiments were conducted on animals infected with the "pylori spongiform bacterium", the leading cause of stomach cancer.
H. coli infection is generally common in childhood and is a common cause of gastrointestinal ulcers in more than half of the world's population.
After treatment of the infected animals with the help of DFMO, it was found that the drug was acting directly to reduce this bacterial infection, thus preventing stomach cancer, compared to other non-infected animals. treated with this medicine.
"Fighting the cancer of the stomach by eliminating H. pylori infection with antibiotics is not necessarily a good idea," said Dr. Keith Wilson, chief of the team. research, to this study.
"The results of this study support the use of dfmo to reduce the activity of bacterial infections and prevent cancer of the stomach, the third leading cause of cancer death in the world."
According to the American Cancer Society, about 28,000 new cases of stomach cancer are diagnosed each year.
Gastric cancer is the most common tumor in the elderly, with approximately 60% of adults diagnosed being aged 65 or older.
Source link
